Marksans Pharma profit jumps 60% on standalone basis for FY26
Standalone net profit reached ₹3,007 million as revenue climbed 14%. Consolidated profit grew at a more modest 10% to ₹4,201 million.
— 5 earlier stories on Marksans Pharma Ltd. →What's new
- Standalone profit after tax rose 60% to ₹3,007m.
- Consolidated profit increased 10% to ₹4,201m.
- Board recommended a final dividend of ₹0.90 per share.
Why this matters
The divergence between standalone and consolidated growth rates suggests that the company's domestic operations outperformed its broader global footprint this year. While the profit growth is strong, the market likely priced in these annual figures well before the formal release.
What we're watching
- Shareholder approval for the proposed dividend at the AGM.
- Whether the foreign exchange gains that boosted FY26 profit persist into FY27.
- Margin sustainability as revenue growth continues.
The full read
Marksans Pharma closed FY26 with a 60% surge in standalone profit after tax to ₹3,007 million, up from ₹1,883 million the prior year. Consolidated performance was more measured, with profit rising 10% to ₹4,201 million. Revenue growth followed a similar pattern, expanding 14% on a standalone basis and 12.5% on a consolidated basis.
It was a strong year.
The company attributed the bottom-line expansion to a mix of higher revenue and foreign exchange gains, while the board proposed a final dividend of ₹0.90 per share, pending shareholder approval at the next annual general meeting. Because these are annual results, the market had largely anticipated the trajectory of the numbers, limiting the potential for a sharp price reaction. The key takeaway is the clear outperformance of the standalone business relative to the consolidated group.
Questions answered
- How did standalone profit compare to the previous year?
- Standalone profit after tax reached ₹3,007 million in FY26, a 60% increase from the ₹1,883 million reported in FY25.
- What was the consolidated profit growth for the year?
- Consolidated profit after tax rose by approximately 10% to ₹4,201 million.
- What dividend did the board recommend?
- The board recommended a final dividend of ₹0.90 per share, which remains subject to approval by shareholders at the upcoming annual general meeting.
- What drove the profit increase?
- The profit growth was supported by a combination of higher revenue and foreign exchange gains.
Marksans Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on MARKSANS →- 26 May 2026 · 1:15 PM IST Marksans Pharma profit jumps 60% on standalone basis for FY26
- 32d ago India Ratings lifts Marksans Pharma outlook to Positive
- 38d ago Marksans plans ₹4,000 cr revenue by FY28, but the call transcript adds nothing new
- 45d ago Marksans shelves ₹100 cr plant, sticks to ₹4,000 cr target
- 46d ago Marksans closes FY26 with record ₹3,033 cr revenue as Q4 UK sales hit all-time high